Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) is a biotechnology company developing therapies for immune-mediated diseases. Its pipeline includes reproxalap, a topical reactive aldehyde species (RASP) modulator being developed for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate… From the company’s description.
In fiscal 2025, Aldeyra Therapeutics, Inc. reported a net loss of $33.85M. Operations used $33.35M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aldeyra Therapeutics, Inc. does
In the company’s own words
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) is a biotechnology company developing therapies for immune-mediated diseases. Its pipeline includes reproxalap, a topical reactive aldehyde species (RASP) modulator being developed for dry eye disease and allergic conjunctivitis; ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa; and RASP modulators ADX-248 and ADX-246 for systemic and retinal diseases. The company’s approach targets RASP, small molecules associated with inflammatory signaling, rather than directly inhibiting or activating individual proteins. Aldeyra has no approved products and has devoted substantially all of its resources to preclinical and clinical development; if its candidates receive approval, it plans to commercialize them directly or through partners. It has granted AbbVie an exclusive option to license and collaborate on reproxalap, but the option had not been exercised as of February 27, 2026. The company’s development portfolio spans ophthalmic and systemic indications, with reproxalap and ADX-2191 among its late-stage candidates. Its website is https://ir.aldeyra.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CONCORD, MA
- Fiscal year end
- December
- CIK
- 1341235
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aldeyra Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aldeyra Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aldeyra Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aldeyra Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aldeyra Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”